442 related articles for article (PubMed ID: 17636363)
1. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
2. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
4. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases.
Kamali S; Cefle A; Sayarlioglu M; Gul A; Inanc M; Ocal L; Aral O; Konice M
Rheumatol Int; 2005 Apr; 25(3):211-4. PubMed ID: 14722731
[TBL] [Abstract][Full Text] [Related]
5. An intravenous immunoglobulin therapy of serious autoimmune rheumatic diseases.
Lukan N; Lazurova I; Racz O; Kristofova B; Tkac I
Bratisl Lek Listy; 2008; 109(11):489-92. PubMed ID: 19205557
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin: adverse effects and safe administration.
Orbach H; Katz U; Sherer Y; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
Lidar M; Masarwa S; Rotman P; Carmi O; Rabinowicz N; Levy Y
Immunol Res; 2018 Dec; 66(6):668-674. PubMed ID: 30565202
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
12. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients.
Nieto-Aristizábal I; Martínez T; Urbano MA; Posso-Osorio I; Plata IF; Garcia-Robledo JE; Aragón CC; Santos VA; Tobón GJ
Lupus; 2019 Nov; 28(13):1566-1570. PubMed ID: 31653191
[TBL] [Abstract][Full Text] [Related]
13. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
14. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
15. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.
Camara I; Sciascia S; Simoes J; Pazzola G; Salas V; Karim Y; Roccatello D; Cuadrado MJ
Clin Exp Rheumatol; 2014; 32(1):41-7. PubMed ID: 24029366
[TBL] [Abstract][Full Text] [Related]
16. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin.
Levy Y; Sherer Y; George J; Langevitz P; Ahmed A; Bar-Dayan Y; Fabbrizzi F; Terryberry J; Peter J; Shoenfeld Y
Int Arch Allergy Immunol; 1999 Jul; 119(3):231-8. PubMed ID: 10436395
[TBL] [Abstract][Full Text] [Related]
17. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
[TBL] [Abstract][Full Text] [Related]
18. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
19. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
